MEMBER

• 

  Representative Director, CEO and founder Akinori Mochizuki, Ph. D.

  After completing his graduate studies at the Graduate School of Pharmaceutical Sciences, Tokyo University of Pharmacy and Life Sciences, he joined Fujirebio Inc. He subsequently earned a Ph.D. in Medicine from Toho University and completed postdoctoral research at the University of Southampton in the UK before joining Sosei Group Corporation.
  
  Since then, he has worked in the biotechnology venture industry, focusing on drug repositioning, business development, and corporate management. Following the acquisition of JITSUBO Co., Ltd., he served as Director, CSO and Head of Business Development, contributing to the development of peptide therapeutics. He subsequently served as Executive Vice President and Head of Business Development at TagCyx Biotechnologies, where he promoted the development of nucleic acid therapeutics.
  
  In January 2021, he founded Vetanic Inc. to realize regenerative medicine for animals using iPS cell technology.
  
  Director, Japanese Society of Veterinary Regenerative Medicine
  Director, Consortium for Advancement of Animal Regenerative Medicine (CARM)

• 

  External Director, CSO and co-founder Kazuya Edamura, DVM, Ph. D. Professor, Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University
  Director of Animal Medical Center (ANMEC) of Nihon University

  Dr. Edamura graduated from the Department of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Nihon University, and obtained a license of Japanese Veterinarian. He has completed the Graduate School of Agricultural and Life Sciences, The University of Tokyo, and obtained Ph.D. Degree. In same years, he joined the Laboratory of Veterinary Surgery, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University as an assistant professor, and is currently a professor.
  He has become a director of Animal Medical Center (ANMEC) of Nihon University where he is also responsible as a Diplomate of Japanese College of Veterinary Surgeons (Dipl. JCVS) in orthopedic surgery. His main research areas are veterinary surgery, musculoskeletal diseases, regenerative medicine, and physical therapy.
  
  Vice President of the Japanese Society of Veterinary Regenerative Medicine
  President of the Consortium for Advancement of Animal Regenerative Medicine (CARM)

• 

  External Director, CTO and co-founder Seiji Shiozawa, DVM, Ph. D. Professor, Institute for Disease Modeling, Kurume University School of Medicine
  Project Associate Professor, Keio University School of Medicine

  Dr. Shiozawa is a co-founder and external director of Vetanic Inc. His expertise lie in stem cell biology, regenerative medicine, and genetic engineering. Together with Dr. Kazuya Edamura, he has developed the method for establishing animal iPS cells, which is Vetanic's core technology.
  He graduated from Nihon University Department of Veterinary Medicine in 2002 and obtained his veterinary license. He then received his Ph.D. in Medicine from the University of Tokyo in 2006. Afterwards, he worked at Hideyuki Okano's lab at Keio University, where he conducted research on neurodegenerative diseases utilizing iPS cell models.
  He is currently a professor at Kurume University School of Medicine and holds a concurrent position as a Project Associate Professor at Keio University School of Medicine.

• 

  External Director Yuto Torii, DVM, MBA Keio Innovation Initiative, Inc. Principal

  Dr. Torii graduated from the School of Veterinary Medicine at Hokkaido University.
  After working as a veterinarian, he moved to sales and marketing at Eli Lilly and Company. Then, after completing an MBA, he started a new career at Elanco. In his role in the Corporate Planning department, he was in charge of the Eli Lilly and Company spin-off project, the Bayer integration project, and the development of corporate strategy.
  In 2020, he joined KII as a venture capitalist specializing in the medical healthcare field. He has been serving as an external director of Vetanic since 2021.

• 

  External Director Noriyuki Kawata, Ph. D. QB Capital, LLC Investment Manager

  Dr. Kawata graduated from the Graduate School of Tokyo Institute of Technology and subsequently obtained a doctorate in social engineering from the Graduate School of Nagoya Institute of Technology. After engaging in R&D of new businesses at a glass manufacturer, he joined a consulting firm. At the firm, he was involved in business operations and patent management, including licensing, as a director of a subsidiary bio-startup.
  In 2016, he joined QB Capital and has engaged not only in investment in deep-tech startups but also in the management of commercialization projects based on university technologies.